Skip to content
Winfred
Back to Investors
B

BrightEdge

Corporate

BrightEdge is the venture and impact investment arm of the American Cancer Society.

Portfolio

1

companies

By category

  • BioTech£89.6M

By location

  • United Kingdom£89.6M

Portfolio companies

C

CellCentric

CellCentric develops novel oral targeted therapies to treat resistant blood cancers.

Recent investments

Series C
$120M

CellCentric raises $120m in Series C funding to advance clinical trials for its oral cancer drug inobrodib.

BioTech

The financing round was co-led by RA Capital Management and Forbion to support late-stage clinical development.

"We are delighted to secure the investment required to continue to advance inobrodib fully and as effectively as possible. This is a significant raise in a challenging market. Today's announcement is a testament to the data we have in hand, the clear clinical and commercial opportunity inobrodib represents, and the strength of our expanded team."
— Will West, CEO
C
CellCentric— United Kingdom
RC
F
AB
RA Capital + 3 others